DFTX

Definium Therapeutics Inc

47.04

Jun 30 • 04:00PM ET +0.49 (1.05%)

Healthcare Biotechnology USA Mid NASD

Peers: KYMR NUVL INCY RYTM APGE KRYS VKTX BMRN AXSM NBIX

| Held by: IWM IWO IBB SCHA VXF FESM IHE CGMM XPH VTWO

Scroll to Statements

Index	RUT
Market Cap	5.13B
Enterprise Value	4.80B
Income	-237.54M
Sales	0.00M
Book/sh	2.68
Cash/sh	3.42
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	106
IPO	Nov 15, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	17.55
P/C	13.74
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.69
Current Ratio	4.69
Debt/Eq	0.15
LT Debt/Eq	0.15
Option/Short	Yes / Yes

EPS (ttm)	-2.50
EPS next Y	-1.62
EPS next Q	-0.56
EPS this Y	-8.79%
EPS next Y	27.76%
EPS next 5Y	30.70%
EPS past 3/5Y	-3.78% -1.48%
Sales past 3/5Y	- -
EPS Y/Y TTM	-164.79%
Sales Y/Y TTM	-
EPS Q/Q	-158.18%
Sales Q/Q	-
Earnings	May 07 AMC
EPS/Sales Surpr.	-44.28% -

Insider Own	5.03%
Insider Trans	-1.81%
Inst Own	69.69%
Inst Trans	8.12%
ROA	-70.22%
ROE	-94.70%
ROIC	-74.32%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	54.79%
SMA50	84.56%
SMA200	169.60%
Trades

Shs Outstand	104.04M
Shs Float	103.58M
Short Float	10.27%
Short Ratio	3.84
Short Interest	10.64M
52W High	47.20 -0.34%
52W Low	6.40 635.00%
Volatility	9.48% 7.84%
ATR (14)	3.06
RSI (14)	89.44
Beta	2.15
Rel Volume	1.56
Avg Volume	2.77M
Volume	4,318,226

Perf Week	30.02%
Perf Month	94.46%
Perf Quarter	168.80%
Perf Half Y	260.18%
Perf YTD	251.31%
Perf Year	624.81%
Perf 3Y	1217.65%
Perf 5Y	-9.10%
Perf 10Y	-
Recom	1.06
Target Price	55.87
Prev Close	46.55
Price	47.04
Change	1.05%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-26	Reiterated	Needham	Buy	$38 → $50
Apr-17-26	Initiated	Stifel	Buy	$30
Apr-10-26	Initiated	Piper Sandler	Overweight	$49
Feb-24-26	Initiated	Wolfe Research	Outperform	$25
Jan-30-26	Initiated	Jefferies	Buy	$30
Oct-13-25	Initiated	Needham	Buy	$28
Aug-04-25	Resumed	Oppenheimer	Outperform	$25
Jan-28-25	Initiated	Evercore ISI	Outperform	$23
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$20
Oct-14-24	Resumed	Leerink Partners	Outperform	$20
Jul-24-24	Initiated	ROTH MKM	Buy	$36
May-29-24	Initiated	Robert W. Baird	Outperform	$27
Apr-15-24	Initiated	Leerink Partners	Outperform	$20
Dec-05-23	Initiated	Canaccord Genuity	Buy	$9
Dec-09-22	Resumed	ROTH Capital	Buy	$25
Nov-16-22	Initiated	RBC Capital Mkts	Outperform	$5
Aug-26-22	Initiated	Oppenheimer	Outperform	$3.50
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight	$3
May-04-22	Initiated	ROTH Capital	Buy	$7
Jun-28-21	Initiated	Maxim Group	Buy	$6

Show Previous Ratings

Jun-26-26 09:30AM	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year (PR Newswire)
07:53AM	FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services (BioPharma Dive)
Jun-25-26 04:15PM	Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters Option to Purchase Additional Shares (Business Wire) +6.31%
Jun-24-26 06:56AM	To Wall Street, psychedelics biotechs are more teammates than rivals (BioPharma Dive) +16.45%
Jun-23-26 09:57PM	Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering (Business Wire)
07:52PM	Loading…
Jun-22-26 07:52PM	DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression (Stocktwits) +49.80%
06:40PM	?? Under the Radar: Definium Shares Propelled by Strong Psychedelic Results (The Wall Street Journal)
04:08PM	This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High. (Investor's Business Daily)
04:01PM	Definium Therapeutics, Inc. Announces Proposed Public Offering (Business Wire)
01:36PM	Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy (Proactive)
07:12AM	Sanofi swaps R&D leaders; Mercks Prometheus deal pays dividends (BioPharma Dive)
06:35AM	DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results What Investors Need To Know (Stocktwits)
May-21-26 07:00AM	Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (Business Wire) +8.53%
May-18-26 10:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-12-26 07:00AM	Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder (Business Wire)
04:01PM	Loading…
May-11-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
May-07-26 04:01PM	Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (Business Wire)
Apr-30-26 04:01PM	Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire) +6.78%
Apr-24-26 11:58AM	Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. (Barrons.com)
Apr-22-26 04:15PM	Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day (Business Wire)
Apr-20-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
10:20AM	Market Minute 4-20-26- Oil Pops, Stocks Slide on Fading Peace Hopes (MoneyShow)
08:26AM	Psychedelic stocks rally with Trump's support (MarketWatch)
05:53AM	Psychedelic stocks soar after Trump signs executive order to fast-track treatments (Investing.com)
Apr-18-26 07:38PM	Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments (Business Wire)
Apr-17-26 04:00AM	Can an LSD candidate do for anxiety what Spravato did for depression? (Pharma Voice)
Apr-09-26 07:00AM	Definium Therapeutics to Participate at Upcoming Investor Conferences and Events (Business Wire)
Apr-06-26 09:08AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-26-26 07:00AM	Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 (Business Wire)
Mar-09-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
10:50AM	Loading…
10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
12:06AM	Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Feb-26-26 11:13PM	Definium Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates (Business Wire)
Feb-24-26 07:01AM	Definium Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Feb-19-26 04:01PM	Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 (Business Wire)
Feb-18-26 09:32PM	Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III (Insider Monkey)
04:25AM	Psychedelics stocks rise as Compass psilocybin drug heads to FDA (BioPharma Dive)
Feb-02-26 04:00PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire) +8.00%
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
Jan-29-26 07:00AM	Definium Therapeutics Appoints Roger Adsett to Board of Directors (Business Wire)
Jan-26-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire) -5.11% +5.88%
09:55AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-20-26 07:00AM	Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care (Business Wire) +11.50%
Dec-29-25 09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-27-25 07:40AM	What's Driving JonesTrading's Bullish View on Mind Medicine (MindMed) Inc. (MNMD) (Insider Monkey)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly) +5.41%
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat)
Dec-18-25 07:01AM	MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire)
Dec-01-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Nov-07-25 12:03AM	Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Nov-06-25 04:01PM	MindMed Reports Q3 2025 Financial Results and Business Updates (Business Wire)
Nov-05-25 07:01AM	MindMed to Participate in Upcoming Investor Conferences (Business Wire)
Nov-03-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire) -13.45%
07:01AM	Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (Business Wire)
Oct-30-25 04:01PM	MindMed to Report Q3 2025 Financial Results on November 6, 2025 (Business Wire) +6.05%
Oct-29-25 10:14PM	Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering (Business Wire)
04:01PM	Mind Medicine (MindMed) Inc. Announces Proposed Public Offering (Business Wire)
Oct-14-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire)
Sep-22-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire) +5.53%
Sep-21-25 09:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-19-25 07:00AM	New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD) (Business Wire)
Sep-08-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Sep-04-25 11:05AM	Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) (Business Wire)
Sep-02-25 03:47AM	Mind Medicine (MindMed) Inc. (MNMD)'s MM120 Earns FDA Breakthrough Status in Anxiety Treatment (Insider Monkey)
Aug-28-25 07:00AM	MindMed to Participate in September Investor Conferences (Business Wire)
Aug-12-25 03:43AM	If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Aug-11-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Aug-07-25 05:25AM	1 Reason to Buy MindMed (MNMD) (Motley Fool)
Aug-01-25 03:36AM	Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com) -7.15%
Jul-31-25 04:01PM	MindMed Reports Q2 2025 Financial Results and Business Updates (Business Wire)
Jul-25-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-24-25 07:00AM	MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025 (Business Wire)
Jul-22-25 12:00PM	All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy (Zacks)
Jul-14-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
12:01AM	This Illegal Psychedelic Is Hailed as a Revolutionary Breakthrough (WSJ)
Jun-09-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Jun-04-25 07:02AM	Why Mind Medicine Gave Investors a Powerful Buzz in May (Motley Fool)
Jun-02-25 09:55AM	Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade (Zacks)
May-28-25 07:00AM	MindMed to Participate in June Investor Conferences (Business Wire)
May-27-25 07:00AM	MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer (Business Wire)
May-21-25 11:18AM	Mind Medicine (MindMed) Inc. (MNMD): Analysts See 285% Upside Potential (Insider Monkey) -8.68%
May-20-25 05:33PM	Why Mind Medicine Stock Vaulted More Than 8% Higher Today (Motley Fool) +8.42%
May-19-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire) +6.21%
May-16-25 04:17PM	Was Jim Cramer Right About Mind Medicine (MNMD) Stock? (Insider Monkey)
May-13-25 09:55AM	Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect? (Zacks)
07:00AM	MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
May-08-25 07:00AM	MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates (Business Wire)
May-07-25 12:33PM	Mind Medicine Q1 2025 Earnings Preview (Seeking Alpha)
Apr-24-25 07:00AM	MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire) +5.24%
Apr-23-25 07:42PM	Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence (Seeking Alpha) +5.34%
Apr-21-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

CEO & DirectorMr. Robert Barrow

M.B.A.Ms. Brandi L. Roberts CPA

M.D.Dr. Daniel Rollings Karlin M.A.

Co-Founder & Clinical AdvisorDr. Scott M. Freeman M.D.

Co-FounderMr. Leonard Latchman

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sullivan Mark	Chief Legal Officer	Jun 25 '26	Sale	45.03	13,008	585,750	320,571	Jun 26 04:30 PM
Roberts Brandi	Chief Financial Officer	Jun 25 '26	Sale	45.03	3,013	135,675	209,487	Jun 26 04:30 PM
Barrow Robert	Chief Executive Officer	Jun 25 '26	Sale	45.03	29,208	1,315,236	1,098,246	Jun 26 04:30 PM
Karlin Daniel	Chief Medical Officer	Jun 25 '26	Sale	45.03	10,035	451,876	503,282	Jun 26 04:30 PM
Wiley Matthew T.	Chief Commercial Officer	Jun 25 '26	Sale	45.03	2,867	129,101	174,633	Jun 26 04:30 PM
MARK SULLIVAN	Officer	Jun 25 '26	Proposed Sale	42.13	13,008	548,027		Jun 25 04:10 PM
MATTHEW THOMAS WILEY	Officer	Jun 25 '26	Proposed Sale	42.13	2,867	120,787		Jun 25 04:09 PM
BRANDI ROBERTS	Officer	Jun 25 '26	Proposed Sale	42.13	3,013	126,938		Jun 25 04:08 PM
DANIEL ROLLINGS KARLIN	Officer	Jun 25 '26	Proposed Sale	42.13	10,035	422,775		Jun 25 04:07 PM
ROBERT B BARROW	Officer	Jun 25 '26	Proposed Sale	42.13	29,208	1,230,533		Jun 25 04:06 PM
Karlin Daniel	Chief Medical Officer	Mar 25 '26	Sale	18.47	8,018	148,092	413,317	Mar 26 06:43 PM
Sullivan Mark	Chief Legal Officer	Mar 25 '26	Sale	18.47	10,702	197,666	271,079	Mar 26 06:42 PM
Barrow Robert	Chief Executive Officer	Mar 25 '26	Sale	18.47	24,431	451,241	752,454	Mar 26 06:42 PM
ROBERT B BARROW	Officer	Mar 25 '26	Proposed Sale	18.47	24,431	451,241		Mar 25 05:41 PM
DANIEL ROLLINGS KARLIN	Officer	Mar 25 '26	Proposed Sale	18.47	8,018	148,092		Mar 25 05:40 PM
MARK SULLIVAN	Officer	Mar 25 '26	Proposed Sale	18.47	10,702	197,666		Mar 25 05:39 PM
Karlin Daniel	Chief Medical Officer	Dec 26 '25	Sale	13.15	5,600	73,623	425,025	Dec 29 05:00 PM
Barrow Robert	Chief Executive Officer	Dec 26 '25	Sale	13.15	25,791	339,072	778,477	Dec 29 05:00 PM
Sullivan Mark	Chief Legal Officer	Dec 26 '25	Sale	13.15	11,276	148,244	282,576	Dec 29 05:00 PM
Karlin, Dan	Officer	Dec 26 '25	Proposed Sale	13.15	5,600	73,623		Dec 29 04:15 PM
Sullivan, Mark	Officer	Dec 26 '25	Proposed Sale	13.15	11,276	148,244		Dec 29 04:15 PM
Barrow, Robert	Officer, Director	Dec 26 '25	Proposed Sale	13.15	25,791	339,072		Dec 29 04:15 PM
Sullivan Mark	Chief Legal Officer	Sep 25 '25	Sale	9.77	11,278	110,186	293,852	Sep 26 05:35 PM
Barrow Robert	Chief Executive Officer	Sep 25 '25	Sale	9.77	25,797	252,037	804,268	Sep 26 05:35 PM
Karlin Daniel	Chief Medical Officer	Sep 25 '25	Sale	9.77	7,704	75,268	430,625	Sep 26 05:34 PM
MARK SULLIVAN	Officer	Sep 25 '25	Proposed Sale	9.77	11,278	110,217		Sep 25 04:43 PM
DANIEL ROLLINGS KARLIN	Officer	Sep 25 '25	Proposed Sale	9.77	7,704	75,289		Sep 25 04:40 PM
ROBERT B BARROW	Officer	Sep 25 '25	Proposed Sale	9.77	25,797	252,106		Sep 25 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

DFTX

Definium Therapeutics Inc

Upgrade your Finviz experience